2011
OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457.
Adelson K, Raptis G, Sparano J, Germain D. OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457. Cancer Research 2011, 71: ot3-01-01-ot3-01-01. DOI: 10.1158/0008-5472.sabcs11-ot3-01-01.Peer-Reviewed Original ResearchMedian progression-free survivalMetastatic breast cancerProgression-free survivalAI therapyPostmenopausal womenMetastatic diseaseAI-resistant metastatic breast cancerResistant metastatic breast cancerAdjuvant AI therapyAI-resistant diseaseClinical benefit ratePrior chemotherapy regimenPhase II studyAdverse event ratesAddition of bortezomibHuman breast cancer cell linesEstrogen-receptor positiveRandomized phase II designsBreast cancer cell linesPhase II designUnfolded protein responseChemotherapy regimenEligible patientsMeasurable diseasePrior chemotherapy
2009
Wound Fluid Induces Cancer Cell Growth: A Mechanism for Recurrence?
Adelson K, Bahadur U, Halpern M, Hauptman E, Barginear M, Bleiweiss I, Ting J, Weltz C, Coomer C, Raptis G, Germain D. Wound Fluid Induces Cancer Cell Growth: A Mechanism for Recurrence? Cancer Research 2009, 69: 3146-3146. DOI: 10.1158/0008-5472.sabcs-09-3146.Peer-Reviewed Original ResearchResidual diseaseLocal recurrenceCancer cell growthBreast cancer cellsWound fluidCancer cell linesAbdominal drainMastectomy patientsSame patientCancer cellsAbdominal flap reconstructionBilateral mastectomy patientsUnilateral mastectomy patientsDifferent breast cancer cell linesBreast cancer cell linesCell linesOccult metastasesCytokine profileSurgical resectionBilateral mastectomyLymph nodesInflammatory componentUnilateral mastectomyPrimary tumorAbdominal fluid